ClinicalTrials.gg
CompletedNCT03342963Updated May 3, 2021Results posted

Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults

A Phase 1 interventional study of ASC-01 and Aripiprazole and sertraline in Healthy Male Adults, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-03.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Male
01

Study summary

To investigate the bioequivalence of aripiprazole between administration of one ASC-01 tablet (aripiprazole 3 mg/sertraline 100 mg combination drug) and concomitant administration of one aripiprazole 3-mg tablet and two sertraline 50-mg tablets (Cohort 1).

To investigate food effect on plasma pharmacokinetics of aripiprazole and sertraline by single oral administration of ASC-01 under a fasting or fed condition (Cohort 2).

02

Conditions studied

  • Healthy Male Adults
03

In context

Lead sponsor

Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subject at the age between 20 and 40 at the time of
  • Subject has a (BMI = body weight [kg]/height [m]2) of ≥18.5 and \<25.0 kg/m2 at screening
  • Subject is providing consent for participation in this trial in writing prior to the start of the procedures related to this trial, and judged by the investigator or subinvestigator to be capable of observing procedures in this trial.

Exclusion criteria

Exclusion Criteria:

  • Subject has a abnormality in physical findings at screening or in medical history that in the investigator's or subinvestigator's opinion may place the subject at risk or interfere with outcome variables including drug absorption, distribution, metabolism, and excretion.
  • Subject is judged by the investigator or subinvestigator to be inappropriate for participation in this trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    ASC-01 in period 1, Aripiprazole and sertraline in period 2

    At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting. At Day 1 in Period II, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting.

    Drug: ASC-01 · Drug: Aripiprazole and sertraline

  • Experimental
    Aripiprazole and sertraline in period 1, ASC-01 in period 2

    At Day 1 in Period I, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting. At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.

    Drug: ASC-01 · Drug: Aripiprazole and sertraline

  • Experimental
    Fasting in period 1, After breakfast in period 2

    At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting. At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast.

    Drug: ASC-01 · Drug: Aripiprazole and sertraline

  • Experimental
    After breakfast in period 1, Fasting in period 2

    At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast. At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.

    Drug: ASC-01 · Drug: Aripiprazole and sertraline

Interventions

  • DrugASC-01

    Aripiprazole 3 mg/sertraline 100 mg combination drug

  • DrugAripiprazole and sertraline

    Drug pages: Aripiprazole · Sertraline

    Aripiprazole 3 mg and sertraline 100 mg

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax) of Aripiprazole in Cohort 1

    Time frame: Baseline, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72,96, 144 and 168h after dosing

  2. Area Under the Plasma Concentration Versus Time Curve 168h (AUC168h) of Aripiprazole in Cohort 1

    Time frame: Baseline, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72,96, 144 and 168h after dosing

  3. Cmax of Aripiprazole and Sertraline in Cohort 2

    Time frame: Baseline, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72,96, 144 and 168h after dosing

  4. AUC168h of Aripiprazole and Sertraline in Cohort 2

    Time frame: Baseline, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72,96, 144 and 168h after dosing

07

Results

Posted May 3, 2021

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: ASC-01 FirstCohort 1: Aripiprazole/Sertraline Concomitant FirstCohort 2: ASC-01 Under Fasted FirstCohort 2: ASC-01 Under Fed First
Started27271010
Completed25251010
Not completed2200
Withdrew: Adverse event1200
Withdrew: Withdrawal by subject1000

Outcome measures

PrimaryPeak Plasma Concentration (Cmax) of Aripiprazole in Cohort 1
Time frame:
Baseline, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72,96, 144 and 168h after dosing
Reported as:
Mean · ng/mL
Peak Plasma Concentration (Cmax) of Aripiprazole in Cohort 1
ng/mLASC-01Aripiprazole/Sertraline Concomitant
Peak Plasma Concentration (Cmax) of Aripiprazole in Cohort 118.8 ± 5.3316.9 ± 4.38
PrimaryArea Under the Plasma Concentration Versus Time Curve 168h (AUC168h) of Aripiprazole in Cohort 1
Time frame:
Baseline, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72,96, 144 and 168h after dosing
Reported as:
Mean · ng*h/mL
Area Under the Plasma Concentration Versus Time Curve 168h (AUC168h) of Aripiprazole in Cohort 1
ng*h/mLASC-01Aripiprazole/Sertraline Concomitant
Area Under the Plasma Concentration Versus Time Curve 168h (AUC168h) of Aripiprazole in Cohort 1783 ± 273779 ± 236
PrimaryCmax of Aripiprazole and Sertraline in Cohort 2
Time frame:
Baseline, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72,96, 144 and 168h after dosing
Reported as:
Mean · ng/mL
Cmax of Aripiprazole and Sertraline in Cohort 2
ng/mLASC-01 Under FastedASC-01 Under Fed
Aripiprazole16.9 ± 5.2316.6 ± 3.74
Sertraline28.9 ± 10.736.5 ± 15.6
PrimaryAUC168h of Aripiprazole and Sertraline in Cohort 2
Time frame:
Baseline, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72,96, 144 and 168h after dosing
Reported as:
Mean · ng*h/mL
AUC168h of Aripiprazole and Sertraline in Cohort 2
ng*h/mLASC-01 Under FastedASC-01 Under Fed
Aripiprazole701 ± 221865 ± 219
Sertraline904 ± 4151060 ± 468

Adverse events

Collected over Treatment-emergent adverse events occurring up to 8 days after dosing date were collected.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 - ASC-010/52 (0%)0/52 (0%)44/52 (84.6%)
Cohort 1 - Aripiprazole/Sertraline Concomitant0/52 (0%)0/52 (0%)43/52 (82.7%)
Cohort 2 - ASC-01 Under Fasted0/20 (0%)0/20 (0%)12/20 (60%)
Cohort 2 - ASC-01 Under Fed0/20 (0%)0/20 (0%)14/20 (70%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCohort 1 - ASC-01Cohort 1 - Aripiprazole/Sertraline ConcomitantCohort 2 - ASC-01 Under FastedCohort 2 - ASC-01 Under Fed
NauseaGastrointestinal disorders39/5238/5211/2010/20
VomitingGastrointestinal disorders20/5217/526/209/20
DiarrhoeaGastrointestinal disorders7/529/523/201/20
Dizziness posturalNervous system disorders0/521/520/202/20
Decreased appetiteMetabolism and nutrition disorders4/523/521/201/20
TachycardiaCardiac disorders3/522/520/200/20
NasopharyngitisInfections and infestations0/520/520/201/20
Orthostatic hypotensionVascular disorders0/520/520/201/20
PharyngitisInfections and infestations0/521/520/200/20
Blood creatine phosphokinase increasedInvestigations1/521/520/200/20

Baseline characteristics

Safety Set: subjects who received investigational medicinal product (IMP) at least once.

Age, Categorical
Age, Categorical(Participants)Cohort 1: ASC-01 FirstCohort 1: Aripiprazole/Sertraline Concomitant FirstCohort 2: ASC-01 Under Fasted FirstCohort 2: ASC-01 Under Fed FirstTotal
<=18 years00000
Between 18 and 65 years2727101074
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: ASC-01 FirstCohort 1: Aripiprazole/Sertraline Concomitant FirstCohort 2: ASC-01 Under Fasted FirstCohort 2: ASC-01 Under Fed FirstTotal
Female00000
Male2727101074
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: ASC-01 FirstCohort 1: Aripiprazole/Sertraline Concomitant FirstCohort 2: ASC-01 Under Fasted FirstCohort 2: ASC-01 Under Fed FirstTotal
Japanese2727101074
Region of Enrollment
Region of Enrollment(Participants)Cohort 1: ASC-01 FirstCohort 1: Aripiprazole/Sertraline Concomitant FirstCohort 2: ASC-01 Under Fasted FirstCohort 2: ASC-01 Under Fed FirstTotal
Japan2727101074
08

Study locations

1 site
  • Clinic of Kyusyu Region
    Fukuoka, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Jan 2018, 1 month.

Results were first posted in May 2021, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2017
First posted
Nov 17, 2017
StartActual
Nov 21, 2017
Primary completionActual
Jan 18, 2018
CompletionActual
Jan 18, 2018
Results first posted
May 3, 2021
Last update
May 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03342963
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Nov 21, 2017
Primary completion
Jan 18, 2018
Completion
Jan 18, 2018
Results posted
May 3, 2021
Last update
May 3, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion